TY  - CHAP
M1  - Book, Section
TI  - Stem Cell & Immune Cell Therapeutics
A1  - Damon, Lloyd E.
A1  - Andreadis, Charalambos Babis
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
PY  - 2020
T2  - Current Medical Diagnosis and Treatment 2020
AB  - Hematopoietic  stem  cell  transplantation  is  a  valuable  treatment  for  a  variety  of  hematologic  malignancies  and  a  few  nonhematologic  cancers  and  nonmalignant  conditions.  In  many  cases,  stem  cell  transplantation  offers  the  only  curative  option  and  can  be  a  life-saving  procedure.  Immune  effector  cell  (eg,  T-cell,  NK-cell)  transplantation  is  an  emerging  approach  in  hematologic  and  solid  malignancies  that  utilizes  the  patient's  own  immune  cells  genetically  engineered  to  recognize  cancer-specific  epitopes  and  incite  an  immune  response  against  cancer.  Two  such  therapies—tisagenlecleucel  and  axicabtagene  ciloleucel—are  FDA-approved  and  directed  against  the  cell  surface  epitope  CD19.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2021/02/26
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1166166393
ER  -